Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MOGAT2 | Q3SYC2 | 5/20 | 0.52 |
| ▸ | MGAT2 | Q10469 | 2/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PKLR | P30613 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | IDH2 | P48735 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.40 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7139520 | 0.92 | MOGAT2 (0.53) | MOGAT2MGAT2PRKDCTLK2PKM | |
| SCHEMBL7136540 | 0.91 | MOGAT2 (0.54) | MOGAT2MGAT2PRKDCTLK2PKM | |
| SCHEMBL7137726 | 0.89 | MOGAT2 (0.57) | MOGAT2MGAT2PRKDCTLK2PKM | |
| SCHEMBL5361507 | 0.88 | MOGAT2 (0.55) | MOGAT2MGAT2PRKDCTLK2PKM | |
| SCHEMBL5367388 | 0.88 | MOGAT2 (0.51) | MOGAT2MGAT2PRKDCBRD4NPC1 | |
| SCHEMBL5373662 | 0.88 | MOGAT2 (0.56) | MOGAT2MGAT2PRKDCTLK2PKM | |
| SCHEMBL5367671 | 0.87 | MOGAT2 (0.54) | MOGAT2MGAT2PRKDCTLK2PKM | |
| SCHEMBL5368848 | 0.86 | MOGAT2 (0.53) | MOGAT2MGAT2PRKDCTLK2PKM | |
| SCHEMBL7135590 | 0.86 | MOGAT2 (0.55) | MOGAT2MGAT2PRKDCTLK2PKM | |
| SCHEMBL5362884 | 0.86 | MGAT2 (0.51) | MOGAT2MGAT2PRKDCTLK2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
| US-6506763-B2 | Useful in prevention and treatment of protein kinase related disorders such as cancer | SUGEN, INC. | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | MOGAT2 1159/4885MGAT2 4714/4885LRRK2 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.